Stem Cell Clinic

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

MALVERN, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 16,000 shares of its common stock to nine newly-hired employees, with a grant date of August 6, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

View original post here:
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

By Global News Feed

HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended June 30, 2024 and provided business highlights.

More here:
Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

By Global News Feed

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2024, and provided a general business update.

Link:
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

By Global News Feed

Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024

See the rest here:
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

By Global News Feed

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) is disappointed in the decision made by the US Food and Drug Administration (USFDA) to request that Lykos Therapeutics complete a third confirmatory Phase 3 trial prior to allowing the approval of MDMA assisted therapy (MDMA-AT) for the treatment of Post Traumatic Stress Disorder.

See the original post:
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

eLabNext and US Lab Partners Enhance Digital Infrastructure for Life Science Companies

By Global News Feed

BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- eLabNext, an Eppendorf Group Company offering a flexible Digital Laboratory Platform equipped with a Laboratory Inventory Management System (LIMS) and Electronic Lab Notebook (ELN), announced today that they’ve entered into a “preferred vendor” partnership with US Lab Partners, a strategic consulting and advisory firm that provides life sciences companies with best-in-class labs, facilities, and EH&S programs.

Read the original post:
eLabNext and US Lab Partners Enhance Digital Infrastructure for Life Science Companies

→←